In just 2 WEEKS (!) I’ll run the Chicago Marathon with @LLSusa in honor of BMT patients of @DukeHMCT and @AtriumHealthWFB. As we close out blood cancer awareness month, please consider supporting these incredible patients!! ❤️ 🩸 https://t.co/XKZCUHimnh
#TwitteRx#Oncopharm#LLS
In just 2 WEEKS (!) I’ll run the Chicago Marathon with @LLSusa in honor of BMT patients of @DukeHMCT and @AtriumHealthWFB. As we close out blood cancer awareness month, please consider supporting these incredible patients!! ❤️ 🩸 https://t.co/XKZCUHimnh
#TwitteRx#Oncopharm#LLS
This weekend I ran 10 miles for the Tar Heels and in a few months I’ll run 26.2 for the Leukemia & Lymphoma Society 🩸
Join the cause by donating to support those w blood cancers ➡️ https://t.co/36vYqekHsQ…
Any and all donations are SO appreciated💕
#Oncopharm#TwitteRx#LLS
🚨🚨 📢 the data we’ve all been waiting for…drum roll please 👏👏👏 letermovir use til D+200 was shown to be safe & effective in HSCT pt post txp in recent phase 3 RCT‼️ So excited to have this extra data to support use beyond D+100 in this high risk pop! 🎉🎉🎉 #Tandem23@ASTCT
Coming together at #Tandem23 to raise awareness for and recognize patients living with GVHD. Exciting advancements being made but much work left to be done to improve the lives of our BMT patients! #GVHDday#GVHDconnect4hope
➡️ learn more about GVHD at https://t.co/rCyH1ZCOjO
From @CashCatie and others from @wakeforestmed: Multi-faceted initiative decreased the rate of inappropriate treatment of asymptomatic pyuria and bacteriuria in the ED. What’s more? Results were maintained 3 years after the intervention.
📄https://t.co/x4uDMExt4V
First 2 days of (virtual) orientation ✅
Ready to get to work and meet my new colleagues @DukeHMCT@DukeOncRx!! Not sure Petty is as excited as I am though
Check out our newest @WolverHeme Happy Hour Podcast Episode 6 "Dr. StrangeDrug or: How I Learned to Stop Worrying and Love the Asparaginase"
🩸We nerd out about the pharmacology, toxicity management, and WHEN and HOW to use asparaginase activity levels!
https://t.co/4eycm67QAM